Scentre 1st Half Net Profit Rises, Annual Guidance Unchanged
By David Winning
SYDNEY--Scentre said it remains on track to increase its earnings and distribution this year, shrugging off the impact of elevated inflation and a slowing economy.
Scentre, which owns and operates 42 Westfield branded shopping centers, reported a net profit of 403.9 million Australian dollars (US$272.6 million) in the six months through June, up from A$149.4 million a year ago. Funds from operations rose by 2.1% to A$568.2 million in the six-month period.
Management kept its annual guidance unchanged as hopes for an early cut in interest rates fade. Scentre expects funds from operations--a smoothed measure of operating cash flow that excludes depreciation, amortization and gains on asset sales--of between 21.75 Australian cents and 22.25 cents per security in the 12 months through December. If achieved, that would represent growth of up to 5.4% compared with 2023.
It also continues to forecast a distribution of at least 17.2 cents per security.
Write to David Winning at david.winning@wsj.com
(END) Dow Jones Newswires
August 20, 2024 18:47 ET (22:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks